Tirzepatide: The Complete 2026 Guide

Tirzepatide is a dual GIP/GLP-1 receptor agonist made by Eli Lilly. It is the active ingredient in Mounjaro (for type 2 diabetes) and Zepbound (for weight management and obstructive sleep apnea in obesity). In published trials, it has produced the largest weight loss of any FDA-approved medication.

Last updated May 1, 2026.

What Is Tirzepatide?

Tirzepatide is a single peptide that activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Both are gut hormones involved in insulin secretion and appetite regulation. Activating both simultaneously produces larger metabolic effects than GLP-1 activation alone — at least in head-to-head data.

How Tirzepatide Differs from Semaglutide

Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 plus GIP. The SURPASS-2 trial directly compared them: tirzepatide produced larger reductions in HbA1c and weight than semaglutide. The SURMOUNT-1 trial showed tirzepatide 15 mg weekly produced about 22% mean body weight loss versus 15% for semaglutide 2.4 mg in STEP-1.

Tirzepatide Brand Names

Weight Loss Data: SURMOUNT-1 and Beyond

The SURMOUNT-1 trial (NEJM 2022) randomized 2,539 adults with obesity to tirzepatide (5, 10, or 15 mg weekly) or placebo for 72 weeks. Mean weight loss:

• Tirzepatide 5 mg: −15.0%
• Tirzepatide 10 mg: −19.5%
• Tirzepatide 15 mg: −20.9% (other readouts cite ~22% with full adherence)
• Placebo: −3.1%

SURMOUNT-2 examined tirzepatide in adults with both obesity and type 2 diabetes — weight loss was about 14–16% (smaller than in non-diabetic obesity, consistent with broader patterns). SURMOUNT-OSA examined obstructive sleep apnea outcomes in obese patients and supported the FDA's OSA indication for Zepbound.

Diabetes Outcomes: SURPASS Trials

Across the SURPASS-1 through SURPASS-5 trials, tirzepatide consistently produced larger HbA1c reductions than placebo, basal insulin, semaglutide 1 mg, and insulin degludec. Typical HbA1c reduction from baseline: 1.8–2.4%.

Dosing and Titration

• Weeks 1–4: 2.5 mg weekly
• Weeks 5–8: 5 mg weekly
• Then escalation by 2.5 mg every 4 weeks up to 15 mg weekly as tolerated

Many patients stop at a tolerated dose below 15 mg if symptoms are controlled or weight goals are met.

Side Effects of Tirzepatide

Most common: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Profile is similar to semaglutide. Less common but more serious: pancreatitis, gallbladder events, severe hypoglycemia in combination with insulin or sulfonylureas. FDA boxed warning for thyroid C-cell tumors observed in rodents — same contraindications as semaglutide (no MTC, no MEN-2).

Who Should Not Take Tirzepatide

• Personal or family history of medullary thyroid carcinoma
• MEN-2
• History of pancreatitis
• Severe gastroparesis or other significant GI motility disorder
• Pregnancy or planning pregnancy
• Known hypersensitivity to tirzepatide

Cost: Brand vs Compounded

• Brand Zepbound (pen): ~$1,000–1,350/month list
• Brand Zepbound (LillyDirect self-pay vials): ~$349–550/month depending on dose
• Brand Mounjaro: ~$1,070/month
• Compounded tirzepatide via telehealth: ~$299–499/month

How to Get Tirzepatide Prescribed

1. Telehealth platform: video consult, prescription, shipped (compounded) or sent to local pharmacy (brand)
2. LillyDirect: brand Zepbound vials directly from manufacturer at lower cash price
3. Primary care or obesity medicine specialist with insurance prior authorization

Related Reading

• Semaglutide Guide
• Compounded Tirzepatide
• Which GLP-1 Works Best for Weight Loss
• GLP-1 Cost

Sources

• Jastreboff et al. SURMOUNT-1. N Engl J Med 2022. DOI
• Frías et al. SURPASS-2. N Engl J Med 2021.
• Malhotra et al. SURMOUNT-OSA. N Engl J Med 2024.
• FDA prescribing information for Mounjaro and Zepbound.